Peter Hajek

Last updated

Peter Hajek is a British psychologist. He is professor of clinical psychology and director of the Wolfson Institute of Preventive Medicine's Tobacco Dependence Research Unit at Queen Mary University of London. [1] He is known for his research into smoking cessation, [2] including the effectiveness of electronic cigarettes for this purpose. [3]

Contents

Education and academic career

Hajek received his PhD from Charles University in Prague in 1973. In 1982, he moved to England, where he joined the Institute of Psychiatry's Addiction Research Unit. He became a lecturer at Barts and The London School of Medicine and Dentistry in 1992, and became a professor there in 1998. [1]

Scientific work

Hajek is the author of over 250 peer-reviewed papers, and has helped develop treatments for people who are dependent on cigarette smoking. [4] He is known for his research into electronic cigarettes, which, he has said, are "at least as effective as nicotine patches" for smoking cessation in the context of minimum support. [5] In 2014, Hajek and other researchers published a paper criticizing a World Health Organization report on electronic cigarettes published earlier that year, which they said had made "misleading" assumptions. [6] Hajek has told the BBC that "...the risks [of electronic cigarettes] are unlikely, some already proven not to exist, while the benefits are potentially enormous." [6] Also in 2014, Hajek co-authored a Cochrane review of the effectiveness of electronic cigarettes for smoking cessation; the review found limited evidence that they were effective for this purpose. Hajek described the results of this review as "encouraging". [7] In February 2019 he published "A Randomized Trial of E-Cigarettes versus Nicotine-Replacement Therapy" in the New England Journal of Medicine. [8] This study demonstrated that smokers who used e-cigarettes to help them quit were 83% more likely to have quit smoking at one year than those who used conventional nicotine replacement therapy. However, according to a review article by Hussein Traboulsi et al. in May 2020 Hajek's study also resulted in more smokers becoming dual users than succeeded in complete abstinence; "Nonetheless, the continued use of and dependence on nicotine and the creation of dual users were issues in this trial. Among participants with 1-year abstinence, 80% were still using e-cigarettes in the e-cigarette group and 9% were still using nicotine replacement in the nicotine replacement group 52 weeks later. Additionally, while 18% of the e-cigarette users achieved complete abstinence, 25% (110/438) became dual users of e-cigarettes and conventional cigarettes." [9]

Related Research Articles

<span class="mw-page-title-main">Nicotine</span> Chemical stimulant produced by some plants

Nicotine is a naturally produced alkaloid in the nightshade family of plants and is widely used recreationally as a stimulant and anxiolytic. As a pharmaceutical drug, it is used for smoking cessation to relieve withdrawal symptoms. Nicotine acts as a receptor agonist at most nicotinic acetylcholine receptors (nAChRs), except at two nicotinic receptor subunits where it acts as a receptor antagonist.

<span class="mw-page-title-main">Cigarette</span> Small roll of tobacco made to be smoked

A cigarette is a narrow cylinder containing a combustible material, typically tobacco, that is rolled into thin paper for smoking. The cigarette is ignited at one end, causing it to smolder; the resulting smoke is orally inhaled via the opposite end. Cigarette smoking is the most common method of tobacco consumption. The term cigarette, as commonly used, refers to a tobacco cigarette, but the word is sometimes used to refer to other substances, such as a cannabis cigarette or a herbal cigarette. A cigarette is distinguished from a cigar by its usually smaller size, use of processed leaf, different smoking method, and paper wrapping, which is typically white.

<span class="mw-page-title-main">Smoking cessation</span> Process of discontinuing tobacco smoking

Smoking cessation, usually called quitting smoking or stopping smoking, is the process of discontinuing tobacco smoking. Tobacco smoke contains nicotine, which is addictive and can cause dependence. As a result, nicotine withdrawal often makes the process of quitting difficult.

<span class="mw-page-title-main">Vaporizer (inhalation device)</span> Device to vaporize substances for inhalation

A vaporizer or vaporiser, colloquially known as a vape, is a device used to vaporize substances for inhalation. Plant substances can be used, commonly cannabis, tobacco, or other herbs or blends of essential oil. However, they are most commonly filled with a combination propylene glycol, glycerin, and drugs such as nicotine or tetrahydrocannabinol as a liquid solution.

<span class="mw-page-title-main">Nicotine replacement therapy</span> Treatment for tobacco use disorder

Nicotine replacement therapy (NRT) is a medically approved way to treat people with tobacco use disorder by taking nicotine through means other than tobacco. It is used to help with quitting smoking or stopping chewing tobacco. It increases the chance of quitting tobacco smoking by about 55%. Often it is used along with other behavioral techniques. NRT has also been used to treat ulcerative colitis. Types of NRT include the adhesive patch, chewing gum, lozenges, nose spray, and inhaler. The use of multiple types of NRT at a time may increase effectiveness.

<span class="mw-page-title-main">Nicotine patch</span> Transdermal patch that releases nicotine into the body

A nicotine patch is a transdermal patch that releases nicotine into the body through the skin. It is used in nicotine replacement therapy (NRT), a process for smoking cessation. Endorsed and approved by the U.S. Food and Drug Administration (FDA), it is considered one of the safer NRTs available for the treatment of tobacco use disorder.

Nicotine gum is a chewing gum containing the active ingredient nicotine polacrilex. It is a type of nicotine replacement therapy (NRT) used alone or in combination with other pharmacotherapy for smoking cessation and for quitting smokeless tobacco.

Nicorette is the brand name of a number of products for nicotine replacement therapy (NRT) that contain nicotine polacrilex. Developed in the late 1970s in Sweden by AB Leo in the form of a chewing gum, Nicorette was the first nicotine replacement product on the market.

<span class="mw-page-title-main">Cytisine</span> Chemical compound

Cytisine, also known as baptitoxine, cytisinicline, or sophorine, is an alkaloid that occurs naturally in several plant genera, such as Laburnum and Cytisus of the family Fabaceae. It has been used medically to help with smoking cessation. It has been found effective in several randomized clinical trials, including in the United States and New Zealand, and is being investigated in additional trials in the United States and a non-inferiority trial in Australia in which it is being compared head-to-head with the smoking cessation aid varenicline. It has also been used entheogenically via mescalbeans by some Native American groups, historically in the Rio Grande Valley predating even peyote.

NicVAX is an experimental conjugate vaccine intended to reduce or eliminate physical dependence to nicotine. According to the U.S. National Institute of Drug Abuse, NicVAX can potentially be used to inoculate against nicotine addiction. This proprietary vaccine is being developed by Nabi Biopharmaceuticals of Rockville, MD. with the support from the U.S. National Institute on Drug Abuse. NicVAX consists of the hapten 3'-aminomethylnicotine which has been conjugated (attached) to Pseudomonas aeruginosa exotoxin A.

<span class="mw-page-title-main">Nicotine withdrawal</span> Process of withdrawing from nicotine addiction

Nicotine withdrawal is a group of symptoms that occur in the first few weeks after stopping or decreasing use of nicotine. Symptoms include intense cravings for nicotine, anger or irritability, anxiety, depression, impatience, trouble sleeping, restlessness, hunger, weight gain, and difficulty concentrating. Withdrawal symptoms make it harder to quit nicotine products, and most methods for quitting smoking involve reducing nicotine withdrawal. Quit smoking programs can make it easier to quit. Nicotine withdrawal is recognized in both the American Psychiatric Association Diagnostic and Statistical Manual (DSM) and the WHO International Classification of Diseases (ICD).

Tobacco harm reduction (THR) is a public health strategy to lower the health risks to individuals and wider society associated with using tobacco products. It is an example of the concept of harm reduction, a strategy for dealing with the use of drugs. Tobacco smoking is widely acknowledged as a leading cause of illness and death, and reducing smoking is vital to public health.

<span class="mw-page-title-main">Electronic cigarette</span> Device that vaporizes a liquid nicotine solution for inhalation

An electronic cigarette (e-cigarette), or vape, is a device that simulates tobacco smoking. It consists of an atomizer, a power source such as a battery, and a container such as a cartridge or tank. Instead of smoke, the user inhales vapor. As such, using an e-cigarette is often called "vaping". The atomizer is a heating element that vaporizes a liquid solution called e-liquid, which quickly cools into an aerosol of tiny droplets, vapor and air. The vapor mainly comprises propylene glycol and/or glycerin, usually with nicotine and flavoring. Its exact composition varies, and depends on several things including user behavior.

<span class="mw-page-title-main">Nicotine dependence</span> Chronic disease

Nicotine dependence is a state of substance dependence on nicotine. It is a chronic, relapsing disease characterized by a compulsive craving to use the drug despite social consequences, loss of control over drug intake, and the emergence of withdrawal symptoms. Tolerance is another component of drug dependence. Nicotine dependence develops over time as an individual continues to use nicotine. While cigarettes are the most commonly used tobacco product, all forms of tobacco use—including smokeless tobacco and e-cigarette use—can cause dependence. Nicotine dependence is a serious public health problem because it leads to continued tobacco use and the associated negative health effects. Tobacco use is one of the leading preventable causes of death worldwide, causing more than 8 million deaths per year and killing half of its users who do not quit. Current smokers are estimated to die an average of 10 years earlier than non-smokers.

Nicotine Anonymous (NicA) is a twelve-step program founded in 1982 for people desiring to quit smoking and live free of nicotine. As of July 2017, there are over 700 face-to-face meetings in 32 countries worldwide with the majority of these meetings occurring in the United States, Iran, India, Canada, Brazil, the United Kingdom, Australia, Russia and in various online community and social media platforms.. NicA maintains that total abstinence from nicotine is necessary for recovery. NicA defines abstinence as “a state that begins when all use of nicotine ceases.

The health effects of electronic cigarettes (e-cigarettes) include a range of potential risks such as exposure to toxic chemicals, the possibility of increased likelihood of respiratory and cardiovascular diseases, and concerns about their possible role in cancer development. Upon their introduction, there were marketing claims that they were a safer alternative to traditional tobacco products.

The scientific community in the United States and Europe are primarily concerned with the possible effect of electronic cigarette use on public health. There is concern among public health experts that e-cigarettes could renormalize smoking, weaken measures to control tobacco, and serve as a gateway for smoking among youth. The public health community is divided over whether to support e-cigarettes, because their safety and efficacy for quitting smoking is unclear. Many in the public health community acknowledge the potential for their quitting smoking and decreasing harm benefits, but there remains a concern over their long-term safety and potential for a new era of users to get addicted to nicotine and then tobacco. There is concern among tobacco control academics and advocates that prevalent universal vaping "will bring its own distinct but as yet unknown health risks in the same way tobacco smoking did, as a result of chronic exposure", among other things.

Jed Eugene Rose is an American academic professor, inventor and researcher in the field of nicotine and smoking cessation. Rose is presently the President and CEO of the Rose Research Center, LLC in Raleigh, North Carolina. Additionally, he is the Director of the Duke Center for Smoking Cessation at Duke University Medical Center.

Electronic cigarettes are marketed to smoking and non-smoking men, women, and children as being safer than cigarettes. In the 2010s, large tobacco businesses accelerated their marketing spending on vape products, similar to the strategies traditional cigarette companies used in the 1950s and 1960s.

The chemical constituents of different types of snus vary, and population-level studies suggest that the disease risks vary as well. Using snus is harmful to health, although much less than smoking tobacco.

References

  1. 1 2 "Peter Hajek". GRAND Website. Archived from the original on 30 January 2015. Retrieved 5 April 2015.
  2. ↑ "Safe to Quit Smoking Before Surgery, Anytime". Fox News. Reuters. 18 March 2011. Retrieved 5 April 2015.
  3. ↑ "E-cigarettes 'less harmful' than cigarettes". BBC. 31 July 2014. Retrieved 5 April 2015.
  4. ↑ Siggins, Lorna (18 February 2014). "E-cigarettes: the Big White Hope in a life-or-death fight with tobacco". The Irish Times. Retrieved 5 April 2015.
  5. ↑ Gallagher, James (8 September 2013). "E-cigarettes 'as effective' as nicotine patches". BBC News. Retrieved 5 April 2015.
  6. 1 2 Triggle, Nick (5 September 2014). "E-cigarette criticisms 'alarmist' say researchers". BBC News. Retrieved 5 April 2015.
  7. ↑ "Review of evidence finds e-cigarettes may help smokers quit". Reuters. 17 December 2014. Retrieved 5 April 2015.
  8. ↑ Hajek, Peter; Phillips-Waller, Anna; Przulj, Dunja; Pesola, Francesca; Smith, Katie Myers; Bisal, Natalie; Li, Jinshuo; Parrott, Steve; Sasieni, Peter; Dawkins, Lynne; Ross, Louise; Goniewicz, Maciej; Wu, Qi; McRobbie, Hayden J. (30 January 2019). "A Randomized Trial of E-Cigarettes versus Nicotine-Replacement Therapy". New England Journal of Medicine. 380 (7): 629–637. doi: 10.1056/NEJMoa1808779 . PMID   30699054.
  9. ↑ Traboulsi, Hussein; Cherian, Mathew; Abou Rjeili, Mira; Preteroti, Matthew; Bourbeau, Jean; Smith, Benjamin M.; Eidelman, David H.; Baglole, Carolyn J. (15 May 2020). "Inhalation Toxicology of Vaping Products and Implications for Pulmonary Health". International Journal of Molecular Sciences. 21 (10): 3495. doi: 10.3390/ijms21103495 . PMC   7278963 . PMID   32429092.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.